Corpus callosotomy (CC) is used to reduce seizures, primarily in patients with generalized drug resistant epilepsy (DRE). The invasive nature of the procedure contribute to underutilization despite potential superiority to other palliative procedures. The goal of this study was to use a multi-institutional epilepsy surgery database to characterize the use of CC across participating centers.
Data was acquired from the Pediatric Epilepsy Research Consortium (PERC) Surgery Database, a prospective observational study collecting data on children 0-18 years referred for surgical evaluation of DRE across 22 US pediatric epilepsy centers. Patient, epilepsy, and surgical characteristics were collected across multiple CC modalities. Outcomes and complications were recorded and statistically analyzed.
83 patients undergoing 85 CC procedures at 14 participating epilepsy centers met inclusion criteria. Mean age at seizure onset at 2.3 years (0-9.4), mean age for Phase I evaluation and surgical intervention were 9.45 (0.1-20) and 10.46 (0.2-20.6) years. Generalized seizure types were the most common (59%). Complete CC was performed in 88%. The majority of CC (57%) were via open craniotomy, followed by laser interstitial thermal therapy (LiTT) (20%) and mini-craniotomy/endoscopic (mc/e) (22%). Mean operative times were significantly longer for LiTT while mean estimated blood loss was greater in open cases. Complications occurred in 11 (13%) cases and differed significantly between surgical technique (p <0.001). There was no significant difference in length of post-operative stay across approaches.. Mean follow up was 12.8 months (range 1-39). 37 (78.7%) of the cohort undergoing open craniotomy, 10 (58.8%) LiTT and 12 (63.2%) endoscopic experienced favorable Engel outcomes; which was not statistically different.
CC is an effective surgical modality for children with DRE. Regardless of surgical modality, complication rates are acceptable and seizure outcomes generally favorable. Newer, less invasive, surgical approaches may lead to increased adoption of this efficacious therapeutic option for pediatric DRE.
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2025.
All research outputs
#4,879,032
of 29,602,031 outputs
Outputs from Epilepsia
#1,703
of 6,903 outputs
Outputs of similar age
#72,544
of 423,374 outputs
Outputs of similar age from Epilepsia
#19
of 96 outputs
Altmetric has tracked 29,602,031 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,903 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
